secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-197957
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant
--------------------------------------------------------------------------------

- Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.
- She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.
- Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.
- Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/0001193125-26-197957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/acad-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-197957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer